Company Overview
More
Cornerstone Pharmaceutical is a Chinese investment holding company. The company, through its subsidiaries, is mainly engaged in the R & D, production and sales of biopharmaceutical products. The company's main products are tumor immunotherapy and molecular targeted drugs. The company mainly does business in China.
CEO： Ningjun Jiang
Market： Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
02616 CSTONE PHARMA-B
5.0400.0000.00%
YOY
Do not show
(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30(FY)2019/12/31
Assets
Current assets
Inventory
--
30.14M
--
--
--
--
--
--
Accounts receivable
--
50.42M
--
--
--
--
--
--
Advance deposits and other receivables
12.11%
119.82M
23.98%
178.04M
102.12%
106.88M
205.63%
143.6M
Cash and equivalents
41.1%
2.45B
168.51%
3.02B
4.44%
1.73B
60.61%
1.13B
Fixed time deposit-current assets
--
--
-77.56%
358.87M
-76.74%
389.37M
110.12%
1.6B
Secured deposit
--
--
16.13%
720K
16.13%
720K
--
620K
Financial assets at fair value-current assets
-15.3%
10.29M
--
--
3.42%
12.15M
--
--
Special items of current assets
--
--
-39.58%
10.13M
--
--
-78.69%
16.76M
Total current assets
18.47%
2.66B
23.74%
3.57B
-34%
2.24B
79.87%
2.89B
Non-current assets
Property, plant and equipment
64.74%
36.62M
177.53%
39.37M
73.42%
22.23M
-1.99%
14.19M
Long-term receivables
10.76%
57.83M
103.59%
81.99M
148.57%
52.21M
242.97%
40.27M
Intangible assets
833.39%
62.45M
398.77%
6.51M
689.96%
6.69M
45.48%
1.31M
Special items of non-current assets
773.73%
76.54M
678.34%
62.59M
11.72%
8.76M
13763.79%
8.04M
Total non-current assets
159.7%
233.44M
198.5%
190.45M
111.46%
89.89M
134.83%
63.8M
Total assets
23.91%
2.89B
27.52%
3.76B
-32.21%
2.33B
80.79%
2.95B
Liabilities
Current liabilities
Other payables and accrued expenses
32.72%
445.06M
57.65%
708.53M
326.41%
335.35M
380.3%
449.44M
Bank loans and overdrafts
--
5.05M
--
2.66M
--
--
--
--
Financial lease liabilities-current liabilities
509.19%
9.75M
99.17%
8.65M
-72.28%
1.6M
--
4.34M
Deferred income-current liabilities
37.07%
7.21M
72.49%
7.21M
--
5.26M
--
4.18M
Special items of current liabilities
--
--
--
--
--
1.89M
--
--
Total current liabilities
35.74%
467.07M
58.76%
727.05M
307.61%
344.1M
-58.71%
457.96M
Net current assets
15.34%
2.19B
17.14%
2.85B
-42.7%
1.9B
389.96%
2.43B
Total assets less current liabilities
21.86%
2.42B
21.78%
3.04B
-40.75%
1.99B
376.71%
2.49B
Non-current liabilities
Long-term bank loan
184.18%
67.62M
--
54.34M
--
23.79M
--
--
Financial lease liabilities-non-current liabilities
14785.29%
15.18M
--
18.21M
-92.76%
102K
--
--
Deferred income-non-current liabilities
-22.07%
8.47M
-21.63%
8.7M
21.36%
10.87M
46.72%
11.1M
Total non-current liabilities
162.51%
91.27M
631.98%
81.24M
235.34%
34.77M
46.72%
11.1M
Total liabilities
47.37%
558.34M
72.32%
808.29M
299.7%
378.86M
-58%
469.06M
Total assets less total liabilities
19.36%
2.33B
19.06%
2.95B
-41.61%
1.95B
381.55%
2.48B
Total equity and non-current liabilities
21.86%
2.42B
21.78%
3.04B
-40.75%
1.99B
376.71%
2.49B
Equity
Share capital
15.43%
793K
14.56%
787K
1.78%
687K
458.54%
687K
Reserve
19.05%
2.33B
19.06%
2.95B
-41.46%
1.96B
381.54%
2.48B
Legal reserve
19.05%
2.33B
19.06%
2.95B
-41.46%
1.96B
381.54%
2.48B
Special items of shareholders' rights and interests
99.69%
-16K
36.67%
-19K
-19619.23%
-5.13M
--
-30K
Shareholders' Equity
19.36%
2.33B
19.06%
2.95B
-41.61%
1.95B
381.55%
2.48B
Total equity
19.36%
2.33B
19.06%
2.95B
-41.61%
1.95B
381.55%
2.48B
Total equity and total liabilities
23.91%
2.89B
27.52%
3.76B
-32.21%
2.33B
80.79%
2.95B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
--Unqualified Opinion--Unqualified Opinion
Auditor
--Deloitte Guan Huang Chen Fang Accountants--Deloitte Guan Huang Chen Fang Accountants
Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.
The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%